Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

0 of 1 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

N/A

5(100.0%)

5Total

N/A(5)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT06344416Not ApplicableRecruiting

Open Label, Controlled, Post Marketing, Registry Study of Ribociclib (Ribo) Treatment Adherence and Patient Reported Outcomes in Participants Using ReX Technology Platform

Role: lead

NCT06335758Unknown

Non-randomized Observational Study to Evaluate ReX® in the Management of Solid Oral Medication.

Role: lead

NCT03424330Not ApplicableUnknown

Evaluation of ReX-C System in Measurement and Improvement of Patients' Adherence.

Role: lead

NCT04215796Not ApplicableUnknown

Evaluation of the ReX-C System, in Patients Receiving CFTR Modulators for the Treatment of Cystic Fibrosis (CF).

Role: lead

NCT04091711Not ApplicableSuspended

Evaluation of ReX-C® System for Medication Adherence in Oncology Patients Taking Oral Oncolytics

Role: lead

NCT03134001Not ApplicableCompleted

Evaluation of Oral PCA Device - PCoA™ Acute

Role: lead

All 6 trials loaded